FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults
Stock Information for FSD Pharma Inc Subordinate Voting Shares
Loading
Please wait while we load your information from QuoteMedia.